However, limited research on the roles of anlotinib and anti-PD-L1/anti-PD-1 antibody (aPD-L1/aPD-1) within the ovarian cancer tumor microenvironment (TME) has left their clinical efficacy and underlying mechanisms unclear, hindering broader clinical application and regulatory approval. This evidence concerns the gene PDCD1 and neoplasm.